We are happy to share our new collaboration!

In this new publication in Current Medical Research and Opinion, Bart Heeg collaborated to indirectly compare the efficacy of bosutinib with nilotinib and dasatinib in first-line chronic-phase chronic myeloid leukemia.

Because heterogeneity in terms of patient baseline characteristics and imatinib dose escalation are difficult to adjust for in network meta-analyses and anchored matching-adjusted indirect treatment comparisons, an unanchored matching-adjusted indirect treatment comparison was used.

Read the full-text article at: https://lnkd.in/guhf5W7

Geen alternatieve tekst opgegeven voor deze afbeelding